Candesartan improves impaired endothelial function in the human coronary artery

Coronary Artery Disease

Volumn 23, Issue 4, 2012, Pages 278-283

  Iino, Kenji ^a   Watanabe, Hiroyuki ^a   Iino, Takako ^a   Katsuta, Mitsuaki ^b   Koyama, Takashi ^a   Kosaka, Toshimitsu ^a   Terui, Gen ^b   Ito, Hiroshi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

candesartan; coronary flow reserve; endothelial dysfunction; human coronary artery

Indexed keywords

ACETYLCHOLINE; CANDESARTAN; PLACEBO;

ARTERY ENDOTHELIUM; ARTICLE; BLOOD FLOW VELOCITY; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DOPPLER FLOWMETRY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; EVENT FREE SURVIVAL; FEMALE; GUIDE WIRE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD FLOW VELOCITY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE-FREE SURVIVAL; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 84860838195     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328351ab42     Document Type: Article

References (31)

1. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990; 81:1586-1593. (Pubitemid 20158298)
2. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83:391-401.
3. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052. (Pubitemid 32304002)
4. Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents 2005; 3:133-148. (Pubitemid 40514788)
5. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258-265. (Pubitemid 26266107)
6. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90:E58-E65.
7. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35 (1 Pt 2): 501-506. (Pubitemid 30054224)
8. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000; 36:575-580.
9. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354. (Pubitemid 30329123)
10. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
11. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362:759-766. (Pubitemid 37093915)
12. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
13. de Bruyne B, Bartunek J, Sys SU, Pijls NH, Heyndrickx GR, Wijns W. Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. Circulation 1996; 94:1842-1849. (Pubitemid 26349295)
14. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, Heyndrickx GR, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography. Circulation 2001; 104:2401-2406. (Pubitemid 33108371)
15. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328:1659-1664. (Pubitemid 23157347)
16. Kern MJ, de Bruyne B, Pijls NH. From research to clinical practice: current role of intracoronary physiologically based decision making in the cardiac catheterization laboratory. J Am Coll Cardiol 1997; 30:613-620. (Pubitemid 27397637)
17. Kelm M. Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. Am J Physiol Heart Circ Physiol 2002; 282:H1-H5. (Pubitemid 34654128)
18. Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 2001; 38:493-498. (Pubitemid 32721779)
19. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol 2002; 40:703-709. (Pubitemid 34925617)
20. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653-658. (Pubitemid 34851922)
21. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95:588-593. (Pubitemid 27063033)
22. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular sup-eroxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
23. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198:22-28. (Pubitemid 351406364)
24. Desideri G, Bravi MC, Tucci M, Croce G, Marinucci MC, Santucci A, et al. Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Arterioscler Thromb Vasc Biol 2003; 23:1218-1223. (Pubitemid 36871276)
25. Takiguchi S, Ayaori M, Uto-Kondo H, Iizuka M, Sasaki M, Komatsu T, et al. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertens Res 2011; 34:686-692.
26. Hornig B, Kohler C, Schlink D, Tatge H, Drexler H. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hypertension 2003; 41:1092-1095. (Pubitemid 36548608)
27. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103-1107. (Pubitemid 39319009)
28. Takai S, Miyazaki M. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence. Am J Cardiovasc Drugs 2006; 6:363-366. (Pubitemid 46072391)
29. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93:1432-1435. (Pubitemid 38692481)
30. Wago T, Yoshimoto T, Akaza I, Tsuchiya K, Izumiyama H, Doi M, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res 2010; 33:796-801.
31. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)